Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Win

15 Jul 2009 08:42

RNS Number : 6911V
ViaLogy PLC
15 July 2009
 



Buckingham Group Contracts ViaLogy to Develop Multiple 

Oil & Gas Lease Properties 

LondonJuly 16, 2009Vialogy (LSE: VIY) ViaLogy announces that it has signed a multi-site services contract with The Buckingham Group of San Angelo, Texas and with offices in Falmouth, MA. Under this agreement ViaLogy will initially provide analysis on three separate fields for Buckingham oil and gas lease prospects using its proprietary QuantumRD™ reservoir characterization, sizing and subsurface interpretation technology.

The Buckingham Group represents six affiliates, including a drilling company, O&G operator, land management and acquisition company, investment companies and a well service company. Collectively, the group drills about 50 wells per year throughout Texas. The group holds multiple leases with extensive drilling rights throughout Texas.

ViaLogy's deliverables will include characterization of hydrocarbon reservoir boundaries, subsurface formations, lithology, and depth, as well as porosity estimates, and recommended drill locations. QuantumRD provides a competitive advantage over conventional processing techniques in being able to discern subsurface features more accurately. 

Under this contract, Buckingham and ViaLogy will target both exploratory and development wells in the 3000 - 9000 feet plus depth formations. QuantumRD will be used for analysis of multiple subsurface imaging modalities including seismic, geochemistry, magnetic and satellite datasets. Contract terms provide Vialogy with both a service fee and a success fee, paid as a working interest in all three wells. 

Buckingham CEO Darryl Buckingham commented, "We are encouraged by the technology ViaLogy has introduced to the industry and expect that it will mitigate risk and provide us with a critical advantage." He added "We are particularly looking to deploy QuantumRD for reserves on the eastern shelf of the Permian basin where conventional 3-D seismic has been unreliable and difficult due, in part, to the heavily fractured nature of underlying geology. We like ViaLogy's approach to sharing the risk. They will receive a services fee, and when we complete wells to production, they will receive a percentage of the recovery as a success fee." 

Vialogy CEO Robert W. Dean said, "We are delighted to partner with the Buckingham Group and their production and geology teams. They have a very impressive staff with extensive experience and the vertically integrated resources to explore and drill aggressively. This collaboration will allow us to broaden the spectrum of formations where QuantumRD could add significant value." 

Further information from:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756) 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000  

About ViaLogy: Network Centric Signal Processing

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTSFSSWISUSELW
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.